Adverum Biotechnologies, Inc.
ADVM · NASDAQ
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Market Cap | $92,382 | $436,567 | $336,267 | $1,731,154 |
| - Cash | $60,652 | $75,000 | $68,431 | $34,195 |
| + Debt | $91,705 | $74,041 | $106,802 | $102,994 |
| Enterprise Value | $123,435 | $435,608 | $374,638 | $1,799,953 |
| Revenue | $1,000 | $3,600 | $0 | $7,500 |
| % Growth | -72.2% | – | -100% | – |
| Gross Profit | $1,000 | $3,600 | $0 | $7,500 |
| % Margin | 100% | 100% | – | 100% |
| EBITDA | -$135,506 | -$123,298 | -$150,607 | -$141,477 |
| % Margin | -13,550.6% | -3,424.9% | – | -1,886.4% |
| Net Income | -$130,927 | -$122,116 | -$154,536 | -$145,540 |
| % Margin | -13,092.7% | -3,392.1% | – | -1,940.5% |
| EPS Diluted | -6.62 | -2.02 | -2.67 | -1.48 |
| % Growth | -227.7% | 24.3% | -80.4% | – |
| Operating Cash Flow | -$92,462 | -$90,902 | -$108,091 | -$107,831 |
| Capital Expenditures | -$388 | -$808 | -$11,816 | -$15,123 |
| Free Cash Flow | -$92,850 | -$91,710 | -$119,907 | -$122,954 |